<DOC>
	<DOCNO>NCT00100477</DOCNO>
	<brief_summary>The purpose study identify high tolerated dos drug use treat aggressive leukemia , lymphoma multiple myeloma respond standard chemotherapy treatment . The drug use study include drug frequently use treating disease ( mitoxantrone etoposide ) well new drug also show effective ( topotecan ) .</brief_summary>
	<brief_title>Use Topotecan Patients With Refractory Acute Leukemia</brief_title>
	<detailed_description>The purpose study identify high tolerated dos drug use treat aggressive leukemia , lymphoma multiple myeloma respond standard chemotherapy treatment . The drug use study include drug frequently use treating disease ( mitoxantrone etoposide ) well new drug also show effective ( topotecan ) .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>Patients follow disease category consider eligible study : Any acute leukemia beyond initial attempt induce remission relapse Chronic Myelogenous Leukemia Blast Phase Refractory Multiple Myeloma Refractory nonHodgkin 's Hodgkin 's Lymphoma Patients must 14 day beyond prior myelotoxic chemotherapy Several eligibility criterion apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Etoposide</keyword>
	<keyword>Drug Therapy</keyword>
	<keyword>Clinical Trials</keyword>
</DOC>